Prognostic Significance of Immune-checkpoint Molecule PD-L1 in
Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120
Cases

J 2023

Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases

KUBEŠ, Václav; Leoš KŘEN; Filip SOKOL; Jozef MICHALKA; Jan MUŽÍK et al.

Základní údaje

Originální název

Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases

Autoři

KUBEŠ, Václav; Leoš KŘEN; Filip SOKOL; Jozef MICHALKA; Jan MUŽÍK; Tomáš ARPÁŠ; Zdenka KŘENOVÁ a Zdeněk KRÁL

Vydání

In vivo, ATHENS, Greece : International Institute of Anticancer Research, 2023, 0258-851X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.800

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/23:00131588

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Classic Hodgkin lymphoma; PD-L1 expression; treatment; overall survival; relapse

Štítky

14110212, 14110230, 14110321, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 14. 2. 2024 09:43, Mgr. Tereza Miškechová

Anotace

V originále

Background/Aim: Classic Hodgkin lymphoma (cHL) is a common B-cell malignancy. Despite the good prognosis, in some patients the standard chemotherapy and radiotherapy-based approach does not lead to long-term remission, and these patients eventually relapse. Moreover, the primary refractory disease is of major concern regarding prognosis. Patients and Methods: We performed a retrospective analysis to evaluate PD-L1 expression in 120 patients with classic Hodgkin lymphoma (cHL). Results: The median follow-up of the entire group of patients was 90 months. After initial therapy, complete remission was achieved in 113 (94.2%) patients. During the follow-up, cHL relapse/refractory disease was reported in 23 (19.2%) cases. A total of five patients died during the follow-up period, all from cHL progression. When determining PD-L1 expression on Hodgkin-Reed-Sternberg (HRS) cells, 37 cases (30.8%) were evaluated as negative, and 83 cases (69.2%) as positive. In the negative PD-L1 group of patients, no cHL relapse/refractory disease was observed during the follow -up period. However, out of 83 patients with positive PD-L1 expression on HRS cells, 23 (28%) showed relapse/refractory cHL. Conclusion: A significantly higher relapse rate was observed in PD-L1-positive patients diagnosed with cHL.

Návaznosti

MUNI/A/1395/2022, interní kód MU

Název: Personalizovaná léčba v dětské onkologii: multimodální theranostický přístup a „N-of-1 clinical trials“

Investor: Masarykova univerzita, Personalizovaná léčba v dětské onkologii: multimodální theranostický přístup a „N-of-1 clinical trials“

Citovat

KUBEŠ, Václav; Leoš KŘEN; Filip SOKOL; Jozef MICHALKA; Jan MUŽÍK; Tomáš ARPÁŠ; Zdenka KŘENOVÁ a Zdeněk KRÁL. Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases. In vivo. ATHENS: Greece : International Institute of Anticancer Research, 2023, roč. 37, č. 4, s. 1735-1742. ISSN 0258-851X. Dostupné z: https://doi.org/10.21873/invivo.13261.

@article{2306558,
   author = {Kubeš, Václav and Křen, Leoš and Sokol, Filip and Michalka, Jozef and Mužík, Jan and Arpáš, Tomáš and Křenová, Zdenka and Král, Zdeněk},
   article_location = {ATHENS},
   article_number = {4},
   doi = {https://doi.org/10.21873/invivo.13261},
   keywords = {Classic Hodgkin lymphoma; PD-L1 expression; treatment; overall survival; relapse},
   language = {eng},
   issn = {0258-851X},
   journal = {In vivo},
   title = {Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases},
   url = {https://iv.iiarjournals.org/content/37/4/1735},
   volume = {37},
   year = {2023}
}

TY  - JOUR
ID  - 2306558
AU  - Kubeš, Václav - Křen, Leoš - Sokol, Filip - Michalka, Jozef - Mužík, Jan - Arpáš, Tomáš - Křenová, Zdenka - Král, Zdeněk
PY  - 2023
TI  - Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases
JF  - In vivo
VL  - 37
IS  - 4
SP  - 1735-1742
EP  - 1735-1742
PB  - Greece : International Institute of Anticancer Research
SN  - 0258851X
KW  - Classic Hodgkin lymphoma
KW  - PD-L1 expression
KW  - treatment
KW  - overall survival
KW  - relapse
UR  - https://iv.iiarjournals.org/content/37/4/1735
N2  - Background/Aim: Classic Hodgkin lymphoma (cHL) is a common B-cell malignancy. Despite the good prognosis, in some patients the standard chemotherapy and radiotherapy-based approach does not lead to long-term remission, and these patients eventually relapse. Moreover, the primary refractory disease is of major concern regarding prognosis. Patients and Methods: We performed a retrospective analysis to evaluate PD-L1 expression in 120 patients with classic Hodgkin lymphoma (cHL). Results: The median follow-up of the entire group of patients was 90 months. After initial therapy, complete remission was achieved in 113 (94.2%) patients. During the follow-up, cHL relapse/refractory disease was reported in 23 (19.2%) cases. A total of five patients died during the follow-up period, all from cHL progression. When determining PD-L1 expression on Hodgkin-Reed-Sternberg (HRS) cells, 37 cases (30.8%) were evaluated as negative, and 83 cases (69.2%) as positive. In the negative PD-L1 group of patients, no cHL relapse/refractory disease was observed during the follow -up period. However, out of 83 patients with positive PD-L1 expression on HRS cells, 23 (28%) showed relapse/refractory cHL. Conclusion: A significantly higher relapse rate was observed in PD-L1-positive patients diagnosed with cHL.
ER  -

KUBEŠ, Václav; Leoš KŘEN; Filip SOKOL; Jozef MICHALKA; Jan MUŽÍK; Tomáš ARPÁŠ; Zdenka KŘENOVÁ a Zdeněk KRÁL. Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases. \textit{In vivo}. ATHENS: Greece : International Institute of Anticancer Research, 2023, roč.~37, č.~4, s.~1735-1742. ISSN~0258-851X. Dostupné z: https://doi.org/10.21873/invivo.13261.

Přehled o publikaci